Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.68 Million SEK | 57.4% |
| 2022 | -12.67 Million SEK | 9.1% |
| 2021 | -13.85 Million SEK | -13.34% |
| 2020 | -12.26 Million SEK | -22.3% |
| 2019 | -9.42 Million SEK | 28.93% |
| 2018 | -12.67 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.95 Million SEK | -8.7% |
| 2024 Q2 | -923 Thousand SEK | 58.24% |
| 2023 Q1 | -2.59 Million SEK | -32.47% |
| 2023 FY | - SEK | 57.4% |
| 2023 Q4 | -2.67 Million SEK | -24436.36% |
| 2023 Q2 | -160 Thousand SEK | 93.83% |
| 2023 Q3 | 11 Thousand SEK | 106.88% |
| 2022 Q4 | -1.95 Million SEK | -0.36% |
| 2022 Q3 | -1.95 Million SEK | 46.33% |
| 2022 Q2 | -3.63 Million SEK | 15.71% |
| 2022 Q1 | -4.31 Million SEK | -24.57% |
| 2022 FY | - SEK | 9.1% |
| 2021 Q1 | -3.18 Million SEK | 0.0% |
| 2021 FY | - SEK | -13.34% |
| 2021 Q2 | -4.05 Million SEK | -27.4% |
| 2021 Q4 | -3.46 Million SEK | -30.23% |
| 2021 Q3 | -2.66 Million SEK | 34.39% |
| 2020 FY | - SEK | -22.3% |
| 2019 FY | - SEK | 28.93% |
| 2018 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 95.223% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 100.894% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 100.894% |
| Arcoma AB | 6.24 Million SEK | 158.963% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 95.906% |
| BICO Group AB (publ) | 322.3 Million SEK | 101.143% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 105.584% |
| CellaVision AB (publ) | 207.24 Million SEK | 101.778% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 94.615% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 86.816% |
| C-Rad AB (publ) | 48.9 Million SEK | 107.533% |
| Duearity AB (publ) | -24.77 Million SEK | 85.133% |
| Dignitana AB (publ) | -264 Thousand SEK | -1295.454% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 95.799% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.062% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 94.522% |
| Iconovo AB (publ) | -35.33 Million SEK | 89.574% |
| Integrum AB (publ) | 8.76 Million SEK | 142.047% |
| Luxbright AB (publ) | -23.86 Million SEK | 84.564% |
| Mentice AB (publ) | 28.87 Million SEK | 112.759% |
| OssDsign AB (publ) | -122.02 Million SEK | 96.981% |
| Paxman AB (publ) | 31.22 Million SEK | 111.797% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 97.552% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 92.892% |
| ScandiDos AB (publ) | -13.35 Million SEK | 72.417% |
| Sectra AB (publ) | 615.06 Million SEK | 100.599% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 92.871% |
| Senzime AB (publ) | -118.82 Million SEK | 96.9% |
| SpectraCure AB (publ) | -20.96 Million SEK | 82.431% |
| Stille AB | 56.04 Million SEK | 106.574% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.884% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 102.911% |